Phaseline

Companies › Ono Pharmaceutical

Ono Pharmaceutical: clinical trials, targets and expected readouts

18 active drug programs in 41 registered trials: 22 Phase 1, 13 Phase 2, 6 Phase 3; Oncology, Neurology, Immunology, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cenobamate
GABA-A receptor; anion channel positive allosteric modulator; Sodium channel alpha subunit inhibitor
GABRA1, GABRB2, GABRG2, GABRB3, GABRA4Phase 3Partial Epilepsy; Epilepsies, PartialJan 2027
ONO-2017
Sodium channel modulator; GABA-A receptor positive allosteric modulator
Ion channels, GABRA1Phase 3Epilepsy, GeneralizedJan 2027
Tirabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Pemphigus; Relapsed/Refractory Primary Central Nervous System Lymphoma; Refractory Primary Central Nervous System Lymphoma; Primary Central Nervous System LymphomaMar 2027
Nivolumab (ONO-4538)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Gastric Cancer; Pan-tumor; Colorectal Cancer; Rhabdoid Tumor …May 2027
Sapablursen (ONO-0530)
Transmembrane protease serine 6 mRNA antisense inhibitor
TMPRSS6Phase 3Polycythemia VeraSep 2028
ONO-2020
Epigenetic regulator
–Phase 2Alzheimer Disease; Agitation Associated With Alzheimer's Disease DementiaDec 2026
ONO-4578
unclear mechanism
–Phase 2Gastric Cancer; Colorectal Cancer; Non-small Cell Lung Cancer; Advanced or Metastatic Solid TumorsJul 2027
ONO-2808–Phase 2Multiple System Atrophy (MSA)Oct 2027
ONO-7703–Phase 2Pan-tumorDec 2027
Magrolimab (ONO-7913)
Leukocyte surface antigen CD47 inhibitor
CD47Phase 1Metastatic Pancreatic Cancer; Unresectable Colorectal CancerJun 2027
ONO-4685–Phase 1Relapsed or Refractory T Cell Lymphoma; Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaAug 2027
ONO-7475
TBD - mechanism unclear for investigational code-named drug
–Phase 1Metastatic Pancreatic CancerSep 2027
ONO-3310–Phase 1Type2 Diabetes MellitusNov 2027
ONO-6414–Phase 1Ulcerative Colitis (UC)Dec 2027
Ripretinib (DCC-2618)
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
KIT, PDGFRAPhase 1Gastrointestinal Stromal TumorsFeb 2028
ONO-4538HSC
PD-1 inhibitor
PDCD1Phase 1Advanced or Metastatic Solid Tumors; Pediatric Malignant Solid Tumor and Epithelioid SarcomaFeb 2028
ONO-7429–Phase 1Solid TumorsJul 2028
ONO-7428–Phase 1Solid TumorJul 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06542731Nivolumab (ONO-4538)Phase 1Non-small Cell Lung CancerOncologyOct 2025
NCT06542731ONO-4578Phase 1Non-small Cell Lung CancerOncologyOct 2025
NCT06881836ONO-2020Phase 2Alzheimer DiseaseNeurologyJul 2026
NCT06803823ONO-2020Phase 2Agitation Associated With Alzheimer's Disease DementiaNeurologyDec 2026
NCT06590896CenobamatePhase 2Epilepsies, PartialNeurologyJan 2027
NCT06579573ONO-2017Phase 3Epilepsy, GeneralizedNeurologyJan 2027
NCT04947319TirabrutinibPhase 2Refractory Primary Central Nervous System LymphomaOncologyMar 2027
NCT05144854Nivolumab (ONO-4538)Phase 3Gastric CancerOncologyMay 2027
NCT06532344Nivolumab (ONO-4538)Phase 1Metastatic Pancreatic CancerOncologyJun 2027
NCT06532344Magrolimab (ONO-7913)Phase 1Metastatic Pancreatic CancerOncologyJun 2027
NCT06256328ONO-4578Phase 2Gastric CancerOncologyJul 2027
NCT05079282ONO-4685Phase 1Relapsed or Refractory T Cell LymphomaOncologyAug 2027
NCT06532331ONO-7475Phase 1Metastatic Pancreatic CancerOncologySep 2027
NCT06532331Nivolumab (ONO-4538)Phase 1Metastatic Pancreatic CancerOncologySep 2027
NCT06696716TirabrutinibPhase 3PemphigusImmunologySep 2027
NCT06547385Nivolumab (ONO-4538)Phase 1Colorectal CancerOncologyOct 2027
NCT06547385ONO-4578Phase 1Colorectal CancerOncologyOct 2027
NCT05923866ONO-2808Phase 2Multiple System Atrophy (MSA)NeurologyOct 2027
NCT07619157ONO-3310Phase 1Type2 Diabetes MellitusGenitourinaryNov 2027
NCT07104032TirabrutinibPhase 3Relapsed/Refractory Primary Central Nervous System LymphomaOncologyDec 2027
NCT04566380Nivolumab (ONO-4538)Phase 2Pan-tumorOncologyDec 2027
NCT06540261Nivolumab (ONO-4538)Phase 1Unresectable Colorectal CancerOncologyDec 2027
NCT07749768ONO-6414Phase 1Ulcerative Colitis (UC)ImmunologyDec 2027
NCT04566380ONO-7703Phase 2Pan-tumorOncologyDec 2027
NCT06540261Magrolimab (ONO-7913)Phase 1Unresectable Colorectal CancerOncologyDec 2027
NCT06948448Nivolumab (ONO-4538)Phase 2Colorectal CancerOncologyFeb 2028
NCT06948448ONO-4578Phase 2Colorectal CancerOncologyFeb 2028
NCT07618377Ripretinib (DCC-2618)Phase 1Gastrointestinal Stromal TumorsOncologyFeb 2028
NCT06548217ONO-4538HSCPhase 1Advanced or Metastatic Solid TumorsOncologyFeb 2028
NCT03155061Nivolumab (ONO-4538)Phase 1Advanced or Metastatic Solid TumorsOncologyMar 2028
NCT03155061ONO-4578Phase 1Advanced or Metastatic Solid TumorsOncologyMar 2028
NCT07594158CenobamatePhase 3Partial EpilepsyNeurologyMar 2028
NCT06541665TirabrutinibPhase 1Primary Central Nervous System LymphomaOncologyApr 2028
NCT07787208ONO-7429Phase 1Solid TumorsOncologyJul 2028
NCT07429266Sapablursen (ONO-0530)Phase 3Polycythemia VeraOncologySep 2028
NCT06622941Nivolumab (ONO-4538)Phase 2Rhabdoid TumorOncologyJan 2029
NCT06547528ONO-4685Phase 1Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaOncologyJan 2029
NCT06816108ONO-7428Phase 1Solid TumorOncologyJul 2029
NCT06936943Nivolumab (ONO-4538)Phase 2Richter's TransformationOncologyJul 2029
NCT07734116ONO-4538HSCPhase 1Pediatric Malignant Solid Tumor and Epithelioid SarcomaOncologyNov 2029
NCT06940791TirabrutinibPhase 2Primary Central Nervous System LymphomaOncologyFeb 2030

Targets

GABRA1 (2) PDCD1 (2) GABRB2 (1) GABRG2 (1) GABRB3 (1) GABRA4 (1) BTK (1) KIT (1) PDGFRA (1) CD47 (1) Ion channels (1) TMPRSS6 (1)

Companies with the same targets

Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group SK Life Science Acacia Pharma Akeso Sedana Medical Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech

Companies built like this

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Haisco Pharmaceutical Group Akeso Merck KGaA Sichuan Baili Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.